Department of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.
Drug Des Devel Ther. 2021 Feb 18;15:689-698. doi: 10.2147/DDDT.S287512. eCollection 2021.
The present study aimed to determine the effectiveness of intravenous dexmedetomidine of different concentrations and to evaluate its maternal and neonatal safety when combined with butorphanol in parturients undergoing cesarean section.
A total of 114 parturients between 24 and 43 years of age, with singleton pregnancy who underwent elective cesarean section under epidural anesthesia, were randomly allocated to four groups: group C received 0.9% sodium chloride after delivery, followed by butorphanol (3 μg·kg·h); patients in groups D1, D2, and D3 received 0.5 μg·kg·h dexmedetomidine after delivery, followed by butorphanol (3 μg·kg·h) combined with dexmedetomidine 0.03, 0.05, and 0.08 μg·kg·h, respectively. The primary outcome was the visual analogue scale (VAS) score at 6 h after delivery when patients were at rest. Secondary outcome measures included VAS after delivery when patients were on movement and uterine cramping, Ramsay sedation scale (RSS), relative infant dose (RID) of dexmedetomidine, satisfaction with analgesia after surgery and symptoms of CNS depression in neonates.
There were no significant differences in patient characteristics among the groups ( > 0.05). The VAS at all timepoints after delivery in groups D2 and D3 were significantly lower than in groups C and D1 ( < 0.001). RSS scores were clearly higher in group D3 than in the other three groups at 6 h and 12 h ( < 0.0001). RID in groups D1, D2, and D3 was 0.171%, 0.197%, and 0.370%, respectively. Compared with group D1, RID was higher in group D3 ( = 0.0079). Degree of satisfaction with analgesia was higher in groups D2 and D3 ( < 0.005).
Continuous intravenous infusion of 0.05 μg·kg·h dexmedetomidine combined with 3 μg·kg·h butorphanol could be safely applied in healthy parturients with satisfactory analgesia after cesarean section without changes in sedation.
本研究旨在确定不同浓度的静脉注射右美托咪定的效果,并评估其与布托啡诺联合用于接受剖宫产术的产妇的母婴安全性。
本研究共纳入 114 名年龄在 24 至 43 岁之间的单胎妊娠产妇,在硬膜外麻醉下行择期剖宫产术,随机分为四组:C 组产妇分娩后给予 0.9%氯化钠,随后给予布托啡诺(3μg·kg·h);D1、D2 和 D3 组产妇分娩后给予右美托咪定 0.5μg·kg·h,随后分别给予布托啡诺(3μg·kg·h)联合右美托咪定 0.03、0.05 和 0.08μg·kg·h。主要结局是产妇在休息时分娩后 6 小时的视觉模拟评分(VAS)。次要结局包括产妇在活动和子宫痉挛时的 VAS、Ramsay 镇静评分(RSS)、右美托咪定的相对婴儿剂量(RID)、术后镇痛满意度和新生儿中枢神经系统抑制症状。
各组产妇的一般特征比较差异无统计学意义(>0.05)。D2 和 D3 组在所有分娩后时间点的 VAS 均显著低于 C 组和 D1 组(<0.001)。D3 组在 6 小时和 12 小时时的 RSS 评分明显高于其他三组(<0.0001)。D1、D2 和 D3 组的 RID 分别为 0.171%、0.197%和 0.370%。与 D1 组相比,D3 组的 RID 更高(=0.0079)。D2 和 D3 组的镇痛满意度更高(<0.005)。
连续静脉输注 0.05μg·kg·h 右美托咪定联合 3μg·kg·h 布托啡诺可安全应用于健康产妇,且剖宫产术后镇痛效果满意,镇静无变化。